This analysis revealed that CRC cell lines harboring KRAS mutations are less responsive to MCL-1 inhibition than the wild type lines, indicating that KRAS activation might be involved in resistance to apoptosis mediated by MCL-1. This evidence concerns the gene KRAS and colorectal carcinoma.